Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Pattison

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
BMJ Open Respiratory Research|June 1, 2025
Biopsy decision for intermediate-high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST studyDavid Fielding, Calvin Sidhu, Mahmoud Alkhater, et al.
European Urology|September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre StudyLouise Emmett, James Buteau, Nathan Papa, et al.
European Urology|April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)Louise Emmett, Nathan Papa, Oliver Sartor, et al.
European Urology Oncology|December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate CancerJames P Buteau, Daniel Moon, Michael T Fahey, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Radiology|April 28, 2026
<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerNarjess Ayati, Nathan Papa, Megan Crumbaker, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06Nathaniel Barry, Roslyn J Francis, Martin A Ebert, et al.
The Lancet. Oncology|June 10, 2026
Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trialJames P Buteau, Daniel Moon, Michael T Fahey, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
BMJ Open Respiratory Research|June 1, 2025
Biopsy decision for intermediate-high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST studyDavid Fielding, Calvin Sidhu, Mahmoud Alkhater, et al.
European Urology|September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre StudyLouise Emmett, James Buteau, Nathan Papa, et al.
European Urology|April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)Louise Emmett, Nathan Papa, Oliver Sartor, et al.
European Urology Oncology|December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate CancerJames P Buteau, Daniel Moon, Michael T Fahey, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Radiology|April 28, 2026
<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerNarjess Ayati, Nathan Papa, Megan Crumbaker, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06Nathaniel Barry, Roslyn J Francis, Martin A Ebert, et al.
The Lancet. Oncology|June 10, 2026
Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trialJames P Buteau, Daniel Moon, Michael T Fahey, et al.
Pageof 8